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Abstract
Introduction—Inflammation and proteolysis crucially contribute to myocardial ischemia and
reperfusion injury. The Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147) and
its ligand Cyclophilin A (CyPA) may be involved in both processes. The aim of the study was to
characterize the role of the CD147 and CyPA interplay in myocardial ischemia/reperfusion (I/R)
injury.
Methods and results—Immunohistochemistry showed enhanced expression of CD147 and
CyPA in myocardial sections from human autopsies of patients who had died from acute
myocardial infarction and from mice at 24 hours after I/R. At 24 hours and 7 days after I/R, the
infarct size was reduced in CD147+/− mice versus CD147+/+ mice (C57Bl/6), in mice (C57Bl/6)
treated with mAb anti-CD147 vs. control mAb, and in CyPA−/− mice vs. CyPA+/+ mice (129S6/
SvEv), all of which being associated with reduced monocyte and neutrophil recruitment at 24h and
with a preserved systolic function at 7 days. Combination of CyPA−/− mice with anti-CD147
treatment did not yield further protection in comparison to either inhibition strategy alone. In vitro,
treatment with CyPA induced monocyte chemotaxis in a CD147- and PI3-kinase dependent
manner and induced monocyte rolling and adhesion to endothelium (HUVEC) under flow in a
CD147-dependent manner.
Conclusion—CD147 and its ligand CyPA are inflammatory mediators after myocardial
ischemia and reperfusion and represent potential targets to prevent myocardial I/R injury.
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Introduction
The most effective treatment for acute myocardial infarction is the early coronary
reperfusion which limits infarct size and preserves cardiac function1–3. Various processes
including the mitochondrial permeability transition pore (mPTP), and oxidative burst of
reactive oxygen species (ROS) production contribute to myocardial injury4–7. Ischemia and
reperfusion (I/R) is accompanied by an extensive inflammatory response with leukocyte
recruitment, induction of a complex inflammatory chemokine network as well as generation
of matrix metalloproteinases (MMP) 8–10. Monocyte infiltration and reorganization of the
extracellular matrix by metalloproteinases (MMPs) is critical for repair mechanisms of the
infarcted myocardium, however, the exact role of leukocyte infiltration and MMPs in these
remodeling processes is not clear yet9–12. While optimal healing requires a balanced MMP-
mediated extracellular matrix turnover13, inadequate MMP activity is thought to trigger an
intensified remodeling process leading to fibrosis and cardiac rupture14, 15.
Cyclophilin A (CyPA) and its receptor, the Extracellular Matrix Metalloproteinase Inducer
(synonyms: CD147, EMMPRIN, basigin) represent a ligand/receptor pair that critically
regulates both leukocyte recruitment and MMP activity16–18. CD147 is involved in
regulating MMPs in various cell types (e.g. tumor cells, monocytes, endothelial cells,
smooth muscle cells), growth factors such as VEGF (tumor cells, endothelial cells) and
NFkappaB-regulated cytokines like IL-6 or M-CSF (monocytes, macrophages, foam
cells)18–23. We have recently found that CD147 is upregulated on circulating monocytes in
patients with acute myocardial infarction and that this regulator modulates MMP-9 and
MT1-MMP activity in monocytes20. Only recently Kandalam et al. showed, that an inhibitor
of MMPs, TIMP-2, reduces myocardial remodeling post infarction primarily via inhibition
of MT1-MMP24. CD147 serves as a surface receptor for CyPA16, 17. CyPA is originally
known as a chaperone and as an intracellular ligand for the immunosuppressive drug,
cyclosporine25. Upon cell activation or cell damage CyPA is released and binds to its
extracellular receptor CD147 on various cell types.26–28 Binding of CyPA to CD147 results
in outside-in signaling and induces NF-kappaB-regulated inflammatory early response genes
including MMP-2 and/or MMP-9 in various cell types including monocytes/macrophages or
smooth muscle cells20, 29, 30. However, to the best of our knowledge, a functional in vivo
relevance for CyPA/CD147 has not been described in myocardial infarction so far. In this
study we show that CyPA/CD147 interaction is a critical mechanism in the pathophysiology
of infarcted myocardium, mediates monocyte chemotaxis and represents a promising
therapeutic target to preserve myocardial function.
Material and Methods
HE and Immunostaining
Paraffin embedded cardiac sections were stained using mAbs anti-CyPA (Abcam,
Cambridge, MA, USA), anti-CD147 (Abcam), anti-Mac-3 (BD Biosciences, San Jose,
California, USA), anti-CD3 (Neomarkers, Fremont, CA, USA), anti-PMN (NIMP-R14,
GeneTex, Inc., Irvine, CA, USA) and isotype control mAb according to standard protocol.
Rabbit anti-rat (Dako, Heverlee, Belgium), goat anti-rabbit (Dako) and donkey anti-rabbit
mAbs (Amersham, Amersham, UK) were used as secondary antibodies depending on the
respective primary antibody. Tissue sections were stained with a streptavidin-biotin-
immunoperoxidase method (StreptABComplex/HRP, liquid DAB, Substrate-Chromogen,
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Dako). Staining with hematoxylin and eosin was according to a standard protocol. Human
cardiac tissue sections were obtained from autopsies of patients with acute myocardial
infarction. The study was approved by the local Ethics Committee (Project-No.
253/2009BO2).
Myocardial ischemia and reperfusion in mice
10 to 12 weeks old mice CyPA+/+ and CyPA−/− (129S6/SvEv, from Jackson laboratory) as
wells as C57Bl/6 and appropriate littermates were used. C57Bl/6 CD147+/− and CD147+/+
mice were a kind gift from Dr. Takashi Muramatsu (Nagoya, Japan)31. After anesthesia of
the mice and preparation of the left anterior descending artery (LAD) the LAD was ligated
for 30min. Successful occlusion was confirmed by visual inspection of color in the apex.
After 24 hours or 7 days of reperfusion the mice were sacrified and the ischemic area (area
at risk, AAR) was quantified by negative staining with 4% Evans Blue (after re-ligation of
the left coronary artery at the level marked by the suture left in place) and the infarcted area
(infarct size, IS) was detected by triphenyltetrazolium staining (Sigma Aldrich, St Louis,
Mo, USA)32. Areas were digitally quantified by videoplanimetry. For in vivo inhibition
experiments, blocking mAb anti-CD147 (RL 73.2) or its isotype control mAb (HB-189)
were injected (1µg per g body weight) at the time of LAD ligation, 6 hrs and 18 hrs post
ischemia, and then daily. Rat anti-mouse mAb anti-CD147 was purified from the RL73.2
hybridoma33 by Genovac (Freiburg, Germany). Isotype control mAb obtained from
American Type Culture Collection16was purified from rat IgG2a hybridoma (HB-189)
(Genovac).
Gelatin zymography and immunoblotting
For extraction of heart samples the free wall of the left ventricle was minced into 1-mm3
pieces and incubated with PBS containing 0.5% Triton X-100 (Sigma) and 0.01% sodium
azide in 4 °C for 18h. The samples were centrifuged (14000 rpm, 10 min, 4 °C) and the
supernatants were harvested. After determining concentration for each sample with the
BioRad DC Protein Assay kit, 100µg were subjected to electrophoresis as described18. For
Western blot analysis tissue of the free wall of the left ventricle was homogenized and
lysated in lysis buffer containing protease inhibitors (Roche, Freiburg, Germany). We used
rabbit anti-CyPA (Abcam) and anti-N-tyrosine (Santa Cruz), followed by a secondary
fluorescence labeled Ab. Phospho-Akt (Ser 473) antibody (Cell signaling) was used in
1:1000 dilution with a fluorescence labelled secondary antibody (licor). Gelatin zymography
and Western blots were quantified by imagJ software.
Echocardiography
was performed using a VEVO 770 ultrasound machine and a 30 Mhz linear transducer as
described recently34.
Chemotaxis and flow chamber assay
Monocytes were isolated as described18. Cell migration was performed using 48-well-
modified Boyden chamber (Neuro Probe Inc) with two compartments separated by a 5 µm
polycarbonate membrane. Monocytes were added to the upper compartments, and medium
containing cardiac homogenates (1:200) from CyPA+/+ mice and CyPA−/− mice or medium
alone was added to the lower chamber. A chemotactic index was calculated for each well by
dividing the number of migrating cells within each test well by the number of cells
migrating to recombinant CyPA (R&D Systems GmbH). Heart homogenates were obtained
from hearts of CyPA+/+ and CyPA−/− mice by using a glass homogenizer and PBS
containing a cocktail of protease inhibitors (Roche). Protein content was equilibrated in
every sample (10µg/µl). For blocking studies anti-EMMPRIN (Ancell, clone UM-8D6) and
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appropriate isotype control were used. LY294002 (Calbiochem, 25µM) and wortmannin
(Calbiochem, 100nM) were used for inhibition of PI3-kinase. For flow chamber assay
human umbilical vein endothelial cells (HUVEC) were allowed to adhere on glass
coverslips until they were confluent and then activated with TNFα (50ng/ml, Peprotech) and
INFγ (20ng/ml, Peprotech) over night (18h). Monocytes (2×105/ml) were perfused over
glass coverslips using arterial shear rates (2000 s−1) as described35.
Statistical analysis
Data are represented as mean±SEM. Difference of means was analyzed by unpaired students
t-Test. Values of p<0.05 were considered significant.
An expanded Methods section is available in the Online Data Supplement at
http://atvb.ahajournals.org.
Results
Expression of CyPA and CD147 is enhanced in infarcted myocardium obtained from
humans and in mice
Cardiac sections from human autopsies of patients who had died from acute myocardial
infarction (AMI) (n = 5) were immunostained with anti-CyPA and anti-CD147 and
compared with specimen from autopsies of three patients with a virtually normal myocardial
histology (HE), who had died of non-cardiac causes (figure 1A, upper panel). Both CyPA
and its receptor CD147 were found to be highly expressed in myocardium derived from
patients with AMI. Whereas CD147 was predominantly expressed on cardiomyocytes,
CyPA appeared to be highly expressed on infiltrating leukocytes adjunct to the infarcted
area (figure 1A, lower panel).
Similar results were obtained in mice with myocardial ischemia and reperfusion injury (I/R)
(figure 1B): Myocardial expression of CyPA and CD147 was substantially enhanced 24h
after a transient 30-minute-ligation of the LAD and was sustained for at least 7 days after
ischemia and reperfusion (I/R) (figure 1B). Similar to human autopsies (figure 1A) CD147
was predominantly present on cardiomyocytes, whereas CyPA was highly expressed on
infiltrating leukocytes consisting mainly of neutrophils (anti-PMN) and macrophages (anti-
MAC-3) (figure 1B). At 7 days CyPA was still present in the scar mainly associated with
macrophages (figure 1B). Interestingly, MMP-9 expression was primarily found in areas of
infiltrating leukocytes both in the acute (d1) and subacute (d7) phase (figure 1B).
These data indicate that both the receptor CD147 and its ligand CyPA are physically present
in substantial amounts in acute myocardial infarction allowing functional activities.
CyPA−/− mice are protected from myocardial I/R injury
Based on the findings that CD147 and its ligand CyPA are upregulated in myocardial
ischemia we analyzed CyPA-deficient mice (CyPA−/−)36 in the model of myocardial
ischemia and reperfusion (figure 2). After a 30min ligation of the left coronary artery (LAD)
infarct size was determined in triphenyltetrazolium-stained myocardium on day 1 and day 7
of reperfusion. As compared to wild-type mice, the infarct size was significantly attenuated
in CyPA-deficient mice at day 1 (figure 2A/B) and at 7 days (figure 2C). These data were
confirmed by echocardiography: The systolic left ventricular function was quantified by
analysis of the fractional area shortening and was found significantly preserved at day 7
(figure 2D).
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CD147+/− mice and mAb anti-CD147-treated WT-mice are largely protected from
myocardial I/R injury
These data encouraged us to further evaluate the role of the cell-membrane-associated
CyPA-receptor, CD147. We studied two additional animal models: i) CD147+/− mice were
analyzed in comparison to CD147+/+ mice and ii) wild-type mice were treated with a mAb
anti-CD147, 37 which is known to solely inhibit the chemotactic activity of CD14738. This
antibody has been well characterized and used in various animal models to inhibit the
interaction between extracellular CyPA and CD14737–39.
Since our breeding did not generate any viable complete CD147−/− mice we decided to
combine the analysis of heterozygote CD147+/− mice with antibody blockade of CD147 in
WT mice. In fact, CD147+/− mice showed a decreased expression of CD147 in splenocytes
(data not shown).
Figure 3B shows that infarct size at day 1 and at day 7 after the I/R is reduced to a similar
extent in both animal models – in mice with reduced CD147 expression (CD147+/−) and in
WT mice treated with anti-CD147 in comparison to their respective control mice (d1: 24%
reduction in CD147+/−, 52% reduction in anti-CD147 treated mice; d7: 36% reduction in
CD147+/−, 46% reduction in anti-CD147 treated mice; figure 3 A/B). Moreover, decreased
expression of CD147 (CD147+/−) or antibody blockade of CD147 both resulted in a
preserved left ventricular systolic function as analyzed by echocardiography (figure 3C).
Interestingly, the use of mAb RL73.2 (anti-CD147), which predominantly blocks the
chemotactic activity of CD147 rather than MMP-induction38 yielded similar results as
achieved in CyPA−/− or CD147+/− mice suggesting that CD147-mediated chemotaxis is an
important pathway in this model of ischemia and reperfusion. In addition, these data suggest
that a pharmacological inhibitory strategy directed against CD147 may have beneficial
effects after myocardial ischemia. In fact, the application of the mAb anti-CD147 directly
before opening the LAD also resulted in a significant reduction of infarct size (figure 3D)
which was found to persist after a period of 28 days (figure 3E).
Anti-CD147 treatment does not yield further protection from I/R in CyPA−/− mice
To further analyze the respective contribution of CyPA and CD147 in this model of I/R, we
have treated CyPA−/− mice with mab anti-CD147. Interestingly, this additional treatment
did not further decrease infarct size in comparison to CyPA−/− treated with control mAb
(figure 4). These data suggest that CyPA and CD147 act through a common pathway in
mediating I/R injury.
CyPA and CD147 regulate macrophage and neutrophil recruitment in I/R injury
Previous data indicated that CyPA and CD147 regulate monocyte and also neutrophil
recruitment in vivo37, 40. Based on our findings that CyPA and CD147 expression is
upregulated in myocardial infarction (figure 1) and that inhibition of the chemotactic activity
of CD147 by a specific mAb largely protects mice from I/R injury over a 28 days period, we
decided to study the influence of CyPA and CD147 on chemotactic activity in more detail.
In fact, the immunohistological analysis of cardiac sections revealed that monocyte and
neutrophil recruitment was largely and to a comparable extent inhibited in the three mouse
models: Neutrophil recruitment at day 1 into the infarct border zone was reduced by 65% in
CyPA−/− mice in comparison to CyPA+/+ mice, by 59% in CD147+/− mice in comparison to
CD147+/+ mice, and by 52% in mice treated with anti-CD147 mAb in comparison to mice
treated with control-mAb (p<0.01, figure 5). Similarly, macrophage recruitment was
reduced by 58% in CyPA−/− mice in comparison to CyPA+/+ mice, by 69% (p<0.01) in
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CD147+/− mice in comparison to CD147+/+ mice, and by 55% (p<0.01) in mice treated with
anti-CD147 mAb in comparison to mice treated with control-mAb (p<0.01, figure 5).
It has been described that the anti-CD147 antibody RL73.2 does not directly influence
MMP-activity37, 38. Interestingly, the analysis of the free wall of the left ventricle by
zymography revealed no significant difference in MMP-2 and MMP-9 activity at 24h after I/
R in anti-CD147 treated mice in comparison to isotype mAb-treated mice (figure 6A/B).
NADPH oxidase-derived reactive oxygen species play a major role for I/R injury41. We
hypothesized that a reduced presence of monocytes and neutrophils may be accompanied by
a reduced oxidative activity. By analyzing the left free wall of the infarcted ventricles after
24h of I/R we found a decreased presence of 3-nitrotyrosine residues as a measure for
oxidative stress in anti-CD147 treated mice compared to their respective controls (figure 6C/
D).
CyPA is a cardiac chemoattractant for monocytes and can induce monocyte adhesion
CyPA has previously been described as a potent chemokine for monocytes.17 We now
studied the relative contribution and relevance of cardiac CyPA for monocyte
chemoattraction. Hearts from wild-type (CyPA+/+) and CyPA−/− mice were explanted and
homogenized as described in material and methods. In a modified boyden chamber CyPA+/+
cardiac homogenates exhibited a strong chemotactic activity for monocytes (figure 7B). In
contrast, CyPA−/− cardiac homogenates only exhibited a weak chemotactic activity (figure
7B). We hypothesized, if CyPA is a relevant factor in the wild-type homogenates the
migration should be inhibited by the presence of recombinant CyPA in the upper chamber
because of an alignment of the CyPA gradient. Indeed, adding 100nM recombinant CyPA
into the upper chamber completely abolished monocytic migration towards CyPA+/+
homogenates. Similar inhibition was achieved by the presence of anti-CD147 into the upper
compartment (figure 7B). These findings suggest that cardiac CyPA can function as a
relevant chemokine in a CD147 dependent manner.
It has been reported that CD147 mediates phosphatidylinositol 3-kinase (PI3K) in tumor
cells and smooth muscle cells 42, 43. Therefore we analyzed the expression of Phospho-Akt
expression in monocytes after CyPA-treatment. Indeed CyPA induced Phospho-Akt.
Additionally induction of Phospho-Akt as well as monocytic migration were abrogated by
PI3-kinase inhibitors wortmannin and LY294002 (figure 7C/D).
Finally we investigated whether CyPA-activated monocytes show enhanced adhesion under
flow conditions. We perfused monocytes over activated human umbilical vein endothelial
cells (HUVECs) in a flow chamber under arterial shear stress and analyzed rolling and
adherent monocytes. CyPA stimulation strongly induced monocyte rolling and adherence
which could be inhibited by preincubation with anti-CD147 antibody (Figure 7E).
Discussion
This manuscript provides evidence that EMMPRIN (CD147) and its ligand CyPA play a
pathophysiological role in the extent of myocardial injury after I/R in mice. By using various
types of mouse models we show that i) expression of CyPA and CD147 is enhanced in
infarcted myocardium obtained from humans and upon I/R injury in mice ii) absence of
CyPA in CyPA−/− mice or decreased expression of CD147 in CD147+/− mice protects mice
from myocardial injury upon I/R with respect to infarct size and systolic function at 7 days,
and iii) pharmacological inhibition of the chemotactic function of CD147 by mAb anti-
CD147 decreases monocyte/macrophage and neutrophil recruitment and infarct size and
preserves left ventricular function. Interestingly, treatment of CyPA−/− mice with mAb anti-
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CD147 yields no additional benefit as compared to otherwise untreated CyPA−/− mice or
mAb anti-CD147-treated WT mice, which suggests a common pathway. The fact, that the
application of the mAb anti-CD147 at the time of reperfusion reduced myocardial injury to a
comparable extent as achieved by treatment before induction of ischemia makes a future
therapeutic strategy in humans at the time of reperfusion (primary PCI) feasible3. The
protective effect of mAb anti-CD147 treatment persisted over at least 28 days.
In all mouse models monocyte/macrophage and neutrophil recruitment were reduced at 24
hours. In addition, oxidative stress as measured by the expression of 3-nitrotyrosine residues
was reduced in mice treated with mAb anti-CD147 as compared to control IgG. This study
cannot definitely (and was not intended to) clarify the general role of leukocyte recruitment
in I/R or of distinct (sub)types of leukocytes. Currently, it is well established that CD147
ligation by its extracellular ligand CyPA activates leukocyte chemotaxis44. Constant and
coworkers have characterized an anti-mouse CD147 mAb, which specifically reduced
leukocyte accumulation and reduced collagen-induced arthritis and bronchial hyperreactivity
in two mouse models, respectively37, 38. In our study, the application of this mAb, which
specifically inhibits the chemotactic activity of CD147 rather than MMP-induction38
severely reduced monocyte/macrophage and neutrophil infiltration into the infarct border
zone, reduced the extent of infarct size and improved left ventricular systolic function. This
specific inhibition of the chemotactic function of CD147 yielded similar effects as found in
mice with decreased expression of CD147 (CD147+/−). Given that different mouse strains
were used, the extent of the inhibition of leukocyte recruitment, infarct size and
improvement of systolic function appears to be similar in CyPA−/− mice. Notably we did
not find any differences in MMP-activity in myocardial samples of CD147+/− mice vs.
CD147+/+ (not shown) or in mice treated either with an anti-CD147 mAb or isotype mAb
(figure 6A/B). The decreased monocyte and neutrophil recruitment may account at least in
part for the observed reduced oxidative stress as assessed by 3-nitrotyrosine expression.
In vitro experiments further support the concept that leukocyte recruitment is a relevant
consequence of CyPA/CD147 interaction: i) Monocytic chemotaxis towards homogenates
from CyPA+/+ hearts was inhibited in the presence of mAb anti-CD147 or by application of
CyPA into the upper compartment and was reduced towards CyPA−/− cardiac homogenates
(figure 7B). ii) CyPA induces Phospho-Akt in monocytes, and inhibition of PI3-kinase by
wortmannin or Ly294002 inhibits CyPA-induced monocyte chemotaxis (figure 7C/D); iii)
apart from chemotaxis, CyPA induces monocyte rolling and adhesion to endothelial cells
(HUVEC) under arterial flow conditions in a CD147-dependent manner (figure 7E).
Notably, an involvement of RISK (reperfusion injury salvage kinases) signalling in
cardioprotection was found in rodents but not in pigs45.
Our data are supported by the work of Berk and coworkers using CyPA−/− mice in two
cardiovascular models: The absence of CyPA was resulted in decreased angiotensin II-
induced aneurysm formation40 as well as in reduced atherosclerosis in ApoE/CyPA−/−
mice46. In both models, the benefit was associated with reduced leukocyte recruitment.
These two studies did not discriminate between intra- and extracellular effects of CyPA nor
investigate the role of CD147.
Here we provide evidence that CyPA and CD147 represent important factors for the
recruitment of neutrophils and monocytes and the resulting myocardial injury upon I/R.
Although we do not provide clear evidence, the link between CyPA and CD147 is supported
by two observations: i) The extent of the effects on leukocyte recruitment, infarct size and
systolic function upon I/R was comparable in the two models that interfere with CyPA
(CyPA−/− vs. CyPA+/+) and CD147 (mAb anti-CD147 vs. isotype IgG). ii) The combined
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inhibitory strategy using mAb anti-CD147 in CyPA−/− mice did not yield any additional
benefit suggesting a common pathway for CyPA and CD147.
There exist some established inhibitors of CyPA such as cyclosporine A (CsA) or its
analogue NIM811. However, in addition to the blockade of extracellular CyPA interactions
with CD147, these drugs interfere with various intracellular CyPA activities such as
inhibition of the calcium-activated protein phosphatase calcineurin (CsA), protein folding
(PPIase activity), and inhibit intracellular CyPD-mediated processes involving the
mitochondrial permeability transition pore (mPTP)5, 6. In specific, CyPD-mediated
inhibition of the mPTP provides a powerful antiischemic protection4. Treatment with CsA or
NIM811 have been shown to effectively protect from myocardial injury in various animal
models of I/R5, 6, 47 and CsA decreases infarct size in patients with acute myocardial
infarction48. It has been suggested that the CyPD-mediated inhibition of the mPTP mainly
accounted for the protective effects.
The focus of our study was to elucidate the role of the extracellular receptor of CyPA,
CD147 (EMMPRIN) by avoiding potential intracellular crossreactions, specifically CyPD-
mediated mitochondrial effects. To our knowledge, there is no known direct interaction
between CyPA and CyPD, namely no effects of CyPA on e.g. the mPTP. Therefore, we
have decided to pharmacologically interfere with the extracellular counterpart of CyPA,
CD147 in addition to studying CD147+/− mice and CyPA−/− mice. The experiments using
CyPA−/− mice clearly demonstrate the relevance of the entire CyPA system and should not
directly influence the CyPD-dependent mPTP. The data using anti-CD147 mAb or the
CD147+/− mice provide clear evidence that the CD147-mediated pathway is of relevance.
In conclusion our data demonstrate that CD147 and its ligand CyPA are crucially involved
in mediating I/R injury and may represent therapeutic targets for myocardial salvage.
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Figure 1. CD147 and CyPA in acute myocardial infarction and I/R injury
(A) Cardiac sections from human autopsies of patients who had died of acute myocardial
infarction (MI) (n = 5) were stained with hematoxylin and eosin (HE) and immunostained
for CyPA and CD147 and compared with specimen from autopsies of three patients, who
had died of non-cardiac reasons and who had a “normal” histology. (B) Serial cardiac
sections of mice after I/R injury at day 1 and day 7 were stained with HE and
immunostained for CD147, CyPA, macrophages (anti-Mac3), neutrophils (anti-PMN) and
MMP-9. Representative images of n≥3 are shown, respectively.
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Figure 2. CyPA−/− mice are protected from myocardial I/R injury
I/R injury was initiated in CyPA+/+ and CyPA−/− mice as described in methods. After 1 day
(d1) or 7 days (d7) mice were sacrificed and analyzed for area at risk and infarct size A)
Evans Blue staining showed a comparable area at risk (related to the left ventricle in %)
after I/R injury at day 1 (d1). B/C) Quantitative analysis of infarct size (related to area at risk
in %) at day 1 (d1, B) and day 7 (d7, C) (n=7). D) Echocardiographic analysis of fractional
area shortening as an indicator for left ventricular systolic function after 7 days (d7) (n=5). *
indicates p<0.05 between groups.
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Figure 3. CD147+/− mice and mAb anti-CD147-treated mice are protected from myocardial I/R
injury
I/R injury was initiated in CD147+/+ and CD147+/− mice (C57BL/6) as well as in C57BL/6
mice with treatment with mAb anti-CD147 or isotype control mAb (1 µg/g i.p., each) as
described in methods. After 1 day (d1) or 7 days (d7) mice were sacrificed and analyzed for
area at risk and infarct size (n≥5, each). (A) Evans Blue staining showed a comparable area
at risk (in % of the respective control) after I/R injury in all groups of mice. (B) Quantitative
analysis of infarct size in % of the respective control (C) Echocardiographic quantitative
analysis of fractional area shortening at day 7 (n≥5), (D/E) C57BL/6 mice were treated with
mAb anti-CD147 or an isotype control mAb (1 µg/g i.p., each) in a more “therapeutic
setting”. First application of the antibody was performed directly before reopening of the
LAD. Quantitative analysis of infarct size (D) at day 1 (n=7) and (E) day 28 (n=5), *
indicates p<0.05.
Seizer et al. Page 14
Arterioscler Thromb Vasc Biol. Author manuscript; available in PMC 2012 June 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 4. Anti-CD147 treatment does not yield further protection from I/R in CyPA−/− mice
I/R injury was initiated in CyPA−/− mice which were treated with mAb anti-CD147 or
isotype control mAb (1 µg/g i.p., each) as described in methods. After 1 day mice were
sacrificed and analyzed for area at risk and infarct size (n=6, each). (A) Evans Blue staining
showed a comparable area at risk (in % of the respective control) after I/R injury. (B)
Quantitative analysis of infarct size in % of area at risk; n.s. indicates not significant
(p>0.05)
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Figure 5. CyPA and CD147 regulate macrophage and neutrophil recruitment in I/R injury
I/R injury was initiated as described in methods. After 1 day (d1) of reperfusion cardiac
sections of mice were analyzed for neutrophil (anti-PMN) and monocyte (anti-Mac3)
infiltration into the infarct border zones. (A) CyPA+/+ vs. CyPA−/− (n=4); (B) C57BL/6
CD147+/+vs. CD147+/− (n=4); (C) anti-CD147 treated mice vs. isotype treated C57BL/6
mice (n=5). * indicates p<0.01.
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Figure 6. Myocardial MMP activity and oxidative stress in anti-CD147 treated mice after I/R
Mice were treated with mAb anti CD147 or isotype IgG and underwent I/R injury as
described in methods. After 24 hours mice were sacrificed and left ventricular myocardial
tissue (free wall) was analyzed. (A) Representative zymography (n=4) and (B) analysis by
optical density (O.D.) shows no difference for MMP-2 and MMP-9. (C/D) Representative
Western blot analysis (n=3) for 3-nitrotyrosine residues and quantification by optical density
* indicates p<0.05
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Figure 7. Cardiac-derived CyPA induces chemoattraction and adhesion of monocytes
(A) Expression of CyPA in cardiac homogenates of CyPA+/+ vs. CyPA−/− mice. One
representative immunoblot (of three) is shown. Actin was used as internal loading control.
(B) Chemotaxis of human monocytes from the upper compartment (top) containing medium,
recombinant CyPA (100nM), isotype-control mAb or anti-CD147 (20µg/ml each) as
indicated towards the lower compartment (bottom) containing medium (negative control,
black bar), recombinant CyPA (100nM, dark bars), medium containing homogenates from
CyPA+/+ (grey bars) or CyPA−/− hearts (white bars) (n=6). (C) Human isolated monocytes
were pretreated with medium, DMSO, wortmannin (100nM) or LY294002 (25µM) as
indicated. Then cells were treated with medium, lipopolysaccharide (positive control, 100ng/
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ml), or CyPA (200nM) as indicated over night. Cells were lysated and Phospho-Akt
expression was analyzed by Western blotting. (D) Chemotaxis of human monocytes from
the upper compartment (top) containing medium, wortmannin (100nM) or Ly294002
(25µM) as indicated towards the lower compartment (bottom) containing medium (negative
control, black bar), recombinant CyPA (100nM, dark bars), or medium containing
homogenates from CyPA+/+ hearts (grey bars) (n=6). (E) After stimulation with medium or
CyPA (100nM, 12h) human monocytes (2×105/ml) were perfused over activated (TNFα and
INFγ as described in material and methods) human umbilical vein endothelial cells
(HUVEC) under arterial shear conditions. Cells were pretreated with medium, isotype or
anti-CD147 mAb (20mg/ml each) as indicated. Monocyte rolling and firm adhesion were
counted for 1 minute (n=5). * indicates p<0.05 between groups.
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